- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We’re Reading: Restricted Abortion Pill; Cigna Drug Price Transparency; New Parkinson Research
Judges reverted steps to make abortion pill mifepristone more accessible, but it is still available; Cigna Group will be offering an option for members that allows more visibility into manufacturer drug pricing and discounts; new research on Parkinson disease could lead to new diagnostics and treatments.
Abortion Pill to Stay Available, With Restrictions
On Wednesday evening, a federal appeals court ruled that the abortion pill mifepristone could stay available, but judges prevented the drug from being sent to patients through the mail and reverted back other steps the government had taken to facilitate access in recent years, reported The New York Times. The appellate panel said the FDA’s approval of the drug could stand because too much time had passed for the plaintiffs, a consortium of groups and doctors opposed to abortion, to dispute that decision. Additionally, the court appeared to take into consideration the government’s view that withdrawing a long-approved drug from the market would have “significant public consequences.”
Cigna to Provide Drug Price Transparency After Scrutiny
Cigna Group is providing clients with more transparency of how much they pay for drugs through its prescription plans, as the industry responds to increasing Washington scrutiny and competition from smaller rivals boasting greater clarity, according to BNN Bloomberg. The company’s pharmacy-benefit management unit will market a “fully transparent” option charging a flat monthly fee for each member, with increased visibility into manufacturers’ prices and discounts. The department, Express Scripts, will also present a plan that caps patients’ out-of-pocket costs from $5 to $45 per prescription, depending on the drug.
Recent Parkinson Research Could Guide New Diagnostics, Treatments
New research funded by the Michael J. Fox Foundation for Parkinson’s Research has caused the clearest evidence so far that the existence of a particular misfolded protein, alpha-synuclein, can be used to ascertain if people have Parkinson, reported STAT News. This new research could be used to create better diagnostics, but more importantly could quickly accelerate a search for treatments. Currently, alpha-synuclein can only be detected by a spinal tap, but scientists hope that it can one day be detected in blood, skin, or nasal swab.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More
